Royalty Pharma plc

NASDAQ:RPRX

25.85 (USD) • At close November 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 564.69537.267567.978596536.313538.202683.971565.748573.463535.955562.049575.7585.773554.963573.027571539510.932500.879457.486464.277457.608434.883
Cost of Revenue 1.6546583.676.513277.137241.228118.8045.67305.061105.7145.67266.5055.7965.7335.671129.3415.7965.73388.012919.16122.33872.2150.033
Gross Profit 563.036531.267-15.622519.487259.176296.974565.167560.078268.402430.241556.379309.195579.977549.23567.356441.659533.204505.199412.867-461.674341.939385.398384.85
Gross Profit Ratio 0.9970.989-0.0280.8720.4830.5520.8260.990.4680.8030.990.5370.990.990.990.7730.9890.9890.824-1.0090.7360.8420.885
Reseach & Development Expenses 0.50.50.5150.50.50.550.525.50.606100.5103.82190.53.1222.641855.7767.63915.8722.71821.45722.991
General & Administrative Expenses 56.7254.70857.65259.18557.23447.63485.69573.22850.69251.84351.5446.16148.58844.92143.156505142.79938.06523.06125.60330.34924.426
Selling & Marketing Expenses 00.2920-0.1850000000000000000000
SG&A 56.7254.70857.6525957.23447.63485.69573.22850.69251.84351.5446.16148.58844.92143.156505142.79938.06523.06125.60330.34924.426
Other Expenses 0-212.429-583.677-1.7071.091118.804308.848305.061105.714190.291-4.82-0.793-0.1070.043801310.261-5.9230.140.232-0.0370.058
Operating Expenses -170.384267.637641.752-17384.871289.362204.999432.576381.253158.163342.331422.283282.721-189.986343.7325828101.586139.449-874.433-68.221129.7493.983
Operating Income 735.074269.63-73.774613151.442248.84478.97295.339192.21227.642219.718153.417303.052744.949229.297314511409.346361.431,331.919532.498327.859430.9
Operating Income Ratio 1.3020.502-0.131.0290.2820.4620.70.1690.3350.4250.3910.2660.5171.3420.40.550.9480.8010.7222.9111.1470.7160.991
Total Other Income Expenses Net 71.284-75.25369.501104.69-29.365102.49630.117-127.37528.204113.805-91.635-99.746-81.25661.806-70.31852.573113.687192.63-252.334114.609-92.471-149.089-34.806
Income Before Tax 806.358194.377-4.273718122.077351.336509.089-610.03220.414491.597128.08353.671221.796806.755158.979367624601.976109.0961,446.528440.027178.77396.094
Income Before Tax Ratio 1.4280.362-0.0081.2050.2280.6530.744-1.0780.3840.9170.2280.0930.3791.4540.2770.6431.1581.1780.2183.1620.9480.3910.911
Income Tax Expense 262.37192.373-9.05122349.963123.711168.3340.1392.582187.093167.95746.974119.867365.97989.86-531.38333.622159.90276.44378.81392.03188.04490.445
Net Income 543.987102.0044.778494.3472.114227.625340.755-610.169217.832304.504-39.8747.904101.929440.77669.119171291442.07471.241,420.396408.982151.713367.444
Net Income Ratio 0.9630.190.0080.8290.1340.4230.498-1.0790.380.568-0.0710.0140.1740.7940.1210.2990.540.8650.1423.1050.8810.3320.845
EPS 1.610.230.0111.110.160.510.76-1.380.360.5-0.0660.0160.241.080.180.440.790.090.24.011.150.431.04
EPS Diluted 1.210.230.0111.110.160.50.76-1.380.360.5-0.0660.0110.241.080.180.440.790.090.24.011.150.431.04
EBITDA 872.86456039.959673.865168.11398.285556.039-606.04267.391538.563225.38883.445308.848750.682234.968393.004516.363415.08367.1631,337.715538.294333.592437.499
EBITDA Ratio 1.5460.502-0.131.0290.3130.5110.7710.2990.3350.7250.4160.2210.5521.410.4360.721.2260.8760.7092.9081.1520.7211.016